Cardiology

New 'gene silencer' drug reduce cholesterol by over 50 percent

The findings come from the largest trial yet to test the safety and effectiveness of this kind of therapy. The technique, known as RNA interference (RNAi) therapy, essentially 'switches off' one of the genes responsible for ...

Cardiology

Evolocumab significantly reduces risk of cardiovascular events

Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or "bad" cholesterol, also significantly lowers the risk of cardiovascular events ...

Cardiology

PCSK9 inhibition with bococizumab yields mixed results

In a clinical program that was terminated early, the experimental PCSK9 inhibitor bococizumab, when given on top of effective statin therapy, had widely varying effects on LDL cholesterol levels and had no benefit on cardiovascular ...

Cardiology

Researchers study a new way to lower LDL cholesterol

In a paper published in Biochemical Pharmacology, Saint Louis University researchers examined the way a nuclear receptor called REV-ERB is involved in regulating cholesterol metabolism. Their findings suggest that drugs targeting ...

page 9 from 17